IMHA Toolkit

Clinical protocols & thrombosis prevention awareness

Independent Educational Resource

Vet Portal → Feline IMHA Dose Reference

Feline IMHA Treatment Reference

Clinical Basis: Derived from feline pharmacological literature and retrospective case series, including the 2026 37-cat non-associative IMHA cohort [Kulmer et al., 2026]. The 2019 ACVIM treatment consensus is canine-specific and should not be applied to cats as a feline treatment protocol.

Feline Evidence Reference

⚠️

Important Clinical Notice This calculator is an educational dose-reference tool based on published veterinary literature. It does not provide a prescription or treatment plan. Drug choice, dose, contraindications, monitoring and treatment duration must be determined by a veterinary surgeon with direct knowledge of the individual patient and checked against current feline formulary information.

⚖️

Weight Parameters

Patient Weight Entry

1. Immunosuppressive Considerations

Prednisolone (Retrospective Literature Reference)

2–4 mg/kg/day reported range

Prednisolone is generally preferred to prednisone in cats because oral prednisolone produces greater systemic exposure. Feline IMHA studies have used heterogeneous starting regimens. Historical cohorts commonly reported approximately 2–4 mg/kg/day, while the 2026 non-associative IMHA cohort used a median initial dose of 4 mg/kg/day [Kulmer et al., 2026]. This range is descriptive, not a feline consensus recommendation; dose selection must be determined by the treating veterinary surgeon and checked against current formulary guidance.

Mycophenolate Mofetil

Literature Context

Mycophenolate has been reported as adjunct immunosuppression in feline IMHA, but direct evidence is limited to very small case reports and pharmacological studies. The 10 mg/kg q12h value shown here is a literature reference only, not an established feline IMHA regimen. Adverse effects, including gastrointestinal signs and reported hepatopathy/pancreatitis, reinforce the need for case-specific monitoring and independent formulary verification.

🚨 FELINE AZATHIOPRINE CAUTION: Azathioprine is generally avoided in cats because feline metabolism of thiopurines differs substantially from dogs and clinically important myelosuppression can occur. Use should not be inferred from canine IMHA protocols.

📋 Adjunct Immunosuppression Considerations

Evidence guiding when to add a second immunosuppressive agent in feline IMHA is limited. Adjunct therapy may be considered in severely affected cats, inadequate response to glucocorticoids, treatment-limiting glucocorticoid adverse effects, or according to specialist judgement. Choice of agent should be individualised.

2. Antithrombotic References — Not Routine IMHA Prophylaxis

Feline IMHA differs from canine IMHA The 2022 CURATIVE consensus classifies feline IMHA itself as a low-risk condition for thrombosis. Antithrombotic therapy is suggested only when additional thrombotic risk factors are present. The drug references below come mainly from feline cardiac and arterial-thromboembolism literature and should not be interpreted as routine treatment recommendations for feline IMHA. [CURATIVE 2022]

Clopidogrel Bisulfate

Published feline antiplatelet reference

Clopidogrel 18.75 mg/cat orally every 24 hours has strong feline evidence for secondary prevention of cardiogenic arterial thromboembolism, including the FAT CAT trial. That evidence does not establish routine use in feline IMHA; any use here is extrapolated and should depend on additional thrombotic risk factors.

Rivaroxaban

0.5–1.0 mg/kg/day reference range

Feline antithrombotic references describe rivaroxaban approximately 0.5–1.0 mg/kg every 24 hours in selected thrombotic/cardiac contexts. This is not a feline IMHA dose recommendation. Evidence in cats with IMHA is insufficient, and use should depend on additional thrombotic risk factors and current antithrombotic/formulary guidance.

⚠️ Prescribing Note (Combination Therapy) Combined antiplatelet and anticoagulant therapy may increase bleeding risk and requires patient-specific assessment and monitoring. Combination therapy should not be inferred as routine treatment for feline IMHA.

💡

Thrombotic Considerations. Current CURATIVE guidance considers feline IMHA itself a low thrombotic-risk condition. Antithrombotic therapy is suggested where additional risk factors for thrombosis exist, rather than as routine prophylaxis for every cat with IMHA.

⚠️ Please independently verify all calculated values before prescribing or administering medication.

📋 Feline Diagnostic & Clinical Guidelines

🔍 Spherocytes in Cats: Diagnostic Pitfalls

Unlike in dogs, spherocytes are difficult to identify reliably in feline blood smears because normal feline erythrocytes have little central pallor. Interpret morphology cautiously and rely on the overall pattern of evidence, including persistent auto-agglutination, direct antiglobulin testing where appropriate, evidence of haemolysis, and investigation for associated disease [Garden et al., 2019].

🧪 Feline IMHA Diagnosis

Feline IMHA may be non-associative or associated with another disease or exposure. Investigation for infectious, neoplastic and other potentially relevant conditions is an important part of the diagnostic work-up [Garden et al., 2019].

🔬 Investigation for Underlying Disease and Infection

Testing for haemotropic Mycoplasma species, FeLV/FIV and other infectious agents should be guided by geography, exposure history, clinical findings and current diagnostic guidance. A diagnosis of non-associative IMHA means that no clinically relevant association was identified during the available investigation; it does not prove that no trigger exists.

📚 What does the feline treatment evidence show?

Glucocorticoids are the usual first-line immunosuppressive treatment reported in feline IMHA. In the 2026 retrospective cohort of 37 cats with non-associative IMHA, the median initial prednisolone dose was 4 mg/kg/day. Twenty-two cats also received ciclosporin at a median initial dose of 10 mg/kg/day, usually started very early in treatment. Cats selected for combination therapy were more severely affected, so the study could not determine whether adding ciclosporin improved outcome [Kulmer et al., 2026].

2026 feline IMHA evidence update In the 37-cat non-associative IMHA cohort, 32/37 cats (86.5%) survived to discharge. Overall mortality was 24.3%, with all deaths occurring within four weeks. Five cats relapsed, four while still receiving immunosuppression, and only two achieved sustained treatment-free remission during long-term follow-up. These findings support careful long-term monitoring but do not establish superiority of prednisolone alone or prednisolone plus ciclosporin. Kulmer et al., 2026 — Evidence Library →

Published Dose References

Immunosuppressant (Prednisolone): Weight (kg) × 2–4 mg/kg/day retrospective literature illustration

Secondary Agent (Mycophenolate): Weight (kg) × 10 mg/kg q12h — published case-report reference only

Platelet Inhibitor (Clopidogrel): 18.75 mg/cat once daily — arterial-thromboembolism literature, not feline IMHA-specific

Factor Xa Block (Rivaroxaban): Weight (kg) × 0.5–1.0 mg/kg once daily — feline antithrombotic reference, not IMHA-specific

Sources: feline pharmacological literature, retrospective case series, CURATIVE antithrombotic guidance and the 2026 non-associative IMHA cohort. View feline IMHA evidence. EDUCATIONAL DOSE-REFERENCE SUPPORT — VERIFY AGAINST CURRENT FELINE FORMULARY SOURCES

Evidence Library

Review the feline IMHA cohort, diagnostic consensus and related evidence underpinning this reference page.

Open Evidence Library →